# Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer

> **NCT00352872** · — · TERMINATED · sponsor: **Indiana University** · enrollment: 23 (actual)

## Conditions studied

- Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00352872
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2005-02
- **Primary completion:** 2009-01-13
- **Final completion:** 2009-01-13
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** This study has been difficult to recruit.
- **Last updated:** 2018-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00352872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00352872, "Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00352872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*